Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide vs Prednisone for Liver Transplant Immune Suppression
NCT03304626Phase 2Completed
- Sponsor
- University of Cincinnati
- Start
- Jun 2017
- Primary completion
- Dec 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of EPI-EE in acute cellular rejection (ACR), sponsored by University of Cincinnati. Started Jun 2017; status: completed.
02
Drugs
EPI-EE
03
Conditions
acute cellular rejection (ACR)
Beyond the preview
Go deeper on NCT03304626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03304626.